Phase II Trial of Weekly Intravenous Gemcitabine Administration With Interferon and Interleukin-2 Immunotherapy for Metastatic Renal Cell Cancer

Abstract

Despite the small sample size, this study demonstrates that gemcitabine combined with standard doses of IFN-alpha and low doses of IL-2 is effective treatment for metastatic renal cell carcinoma. This biotherapy was well tolerated and resulted in an optimum objective response and relatively long-term survival.